ClinConnect ClinConnect Logo
Search / Trial NCT07070050

Continuous vs. Bolus Administration of NSAIDs After Laparoscopic Surgery for Multimodal Analgesia

Launched by FEDERAL RESEARCH AND CLINICAL CENTRE OF INTENSIVE CARE MEDICINE AND REHABILITOLOGY · Jul 7, 2025

Trial Information

Current as of July 23, 2025

Recruiting

Keywords

Nsaid Pain Management Analgesia Postoperative Care Analgesic Drug

ClinConnect Summary

This clinical trial is studying the best way to give a common pain medicine called ibuprofen after laparoscopic surgery, which is a type of surgery done through small cuts. The researchers want to find out if giving ibuprofen continuously through a small tube (called continuous infusion) works better or is safer than giving it in separate doses (called bolus injections). This is important because doctors are trying to reduce the use of stronger pain medicines like opioids after surgery, and ibuprofen is a safer option that might help manage pain effectively.

Adults who are having planned laparoscopic surgery with general anesthesia may be eligible to join the study, as long as they don’t have certain health issues like allergies to ibuprofen, stomach ulcers, severe kidney or liver problems, asthma, blood clotting disorders, or if they are already using strong pain medicines regularly. Participants will be closely monitored after surgery to see how well their pain is controlled and to make sure the medicine is safe for them. This study aims to improve pain care after surgery while minimizing the need for opioid painkillers.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age \> 18 years old
  • Elective laparoscopic surgery
  • General anesthesia
  • Signed informed consent from the patient to participate in the study
  • RASS scale from -2 to +1 on admission to a surgical department or ICU
  • Exclusion Criteria:
  • History of ibuprofen allergy
  • Active erosive or ulcerative lesions of the gastrointestinal tract
  • Chronic use of opioid analgesics or NSAIDs prior to enrollment
  • Chronic kidney disease ≥ 3b stage according to the KDIGO classification
  • Liver dysfunction (three times exceeding the upper reference limit of ALT or AST)
  • A history of bronchial asthma
  • A history of hereditary coagulopathies
  • A history of use of anticoagulants

About Federal Research And Clinical Centre Of Intensive Care Medicine And Rehabilitology

The Federal Research and Clinical Centre of Intensive Care Medicine and Rehabilitology is a leading institution dedicated to advancing the fields of critical care and rehabilitation through innovative research and clinical excellence. With a focus on improving patient outcomes, the Centre conducts rigorous clinical trials and studies that explore cutting-edge therapies and methodologies in intensive care medicine. By fostering collaboration among multidisciplinary teams, the Centre aims to translate scientific findings into practical applications, enhancing the quality of care for patients facing complex medical challenges.

Locations

Moscow, Moscow Region, Russian Federation

Patients applied

0 patients applied

Trial Officials

Valery Likhvantsev, PhD

Principal Investigator

Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported